Haemonetics vs Envista
Envista reported revenue of $2.7 billion in fiscal 2025, 2.0 times Haemonetics' $1.3 billion in fiscal 2026. Haemonetics' revenue fell 2.0% in its latest year, and Envista's grew 8.3%. Haemonetics had an operating margin of 11.8%, against 8.0% at Envista. Free cash flow was $260 million at Haemonetics and $230 million at Envista. Their fiscal years end in different months (March 28 and December 31), so the periods don't line up exactly.
Side by side
| Haemonetics | Envista | |
|---|---|---|
| Latest fiscal year | FY2026, Mar 28, 2026 | FY2025, Dec 31, 2025 |
| Revenue | $1.3B | $2.7B |
| Revenue growth | −2.0% | 8.3% |
| Revenue growth a year, last 5 years | 8.9% | 7.1% |
| Gross margin | 59.0% | 54.7% |
| Operating margin | 11.8% | 8.0% |
| Net margin | 7.3% | 1.7% |
| Free cash flow | $260M | $230M |
| Free cash flow margin | 19.5% | 8.5% |
| Return on capital | 6.7% | 3.2% |
| Net debt to EBITDA | 3.7x | 0.7x |
| Dividends and buybacks | $175M | $167M |
| Change in diluted share count | −6.7% | −1.7% |
| Last close | $119.19 | $23.66 |
| P/E at the last close | 57.6× | 40.8× |
| Insider trades, last 12 months | bought $98,784, sold $0 | sold $510,250 |
| Piotroski F-score | 7 of 9 | 7 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
HaemoneticsEnvista
Operating margin
Percent of revenue
HaemoneticsEnvista
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
HaemoneticsEnvista
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Haemonetics and Envista pages.